STOCK TITAN

Vanguard disaggregates holdings; Exact Sciences (NASDAQ: EXAS) shows 0 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Exact Sciences Corp — Schedule 13G/A (Amendment No. 12)

The Vanguard Group reports 0 shares beneficially owned of Exact Sciences common stock, representing 0% of the class. The filing states Vanguard completed an internal realignment on January 12, 2026, after which certain subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings; reported ownership is zero after realignment.

The filing shows an institutional reallocation: The Vanguard Group states it no longer aggregates beneficial ownership for certain subsidiaries following an internal realignment on January 12, 2026. The report lists 0 shares and 0% of the class.

Implications depend on subsidiary filings; subsequent separate 13G/A entries by named subsidiaries will show which managed accounts retain exposure. Cash‑flow treatment or specific subsidiary amounts are not in this excerpt.

Filing relies on SEC Release No. 34-39538 to disaggregate reporting.

The statement cites SEC Release No. 34-39538, indicating compliance with disaggregated reporting where subsidiaries now report separately. The signer is identified as Ashley Grim, Head of Global Fund Administration, signed 03/26/2026.

Regulatory watchers should review subsequent filings from Vanguard subsidiaries for resumed disclosure of holdings; timing and amounts for those subsidiary reports are not provided here.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does The Vanguard Group report for EXAS ownership?

The Vanguard Group reports 0 shares beneficially owned of Exact Sciences common stock, representing 0% of the class. The filing attributes the change to an internal reorganization effective January 12, 2026, with subsidiaries to report separately.

Why does Vanguard report zero ownership for EXAS now?

Vanguard states an internal realignment on January 12, 2026, after which certain subsidiaries no longer have their holdings aggregated with The Vanguard Group and will report separately under SEC Release No. 34-39538.

Who signed the Schedule 13G/A amendment for EXAS?

Ashley Grim, Head of Global Fund Administration for The Vanguard Group, signed the filing on 03/26/2026. The signature certifies the reporting of 0 shares and the disaggregation statement included in the form.

Does this filing mean Vanguard sold all EXAS shares?

This filing states Vanguard reports 0 shares due to reallocation of reporting among subsidiaries; it does not state whether shares were sold. The excerpt does not disclose cash flows or transactions tied to the change.

Will other Vanguard entities report EXAS holdings separately?

Yes. The filing says certain Vanguard subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538. Specific subsidiary filings and amounts are not included in this excerpt.
Exact Sciences Corp

NASDAQ:EXAS

View EXAS Stock Overview

EXAS Rankings

EXAS Latest News

EXAS Latest SEC Filings

EXAS Stock Data

20.03B
186.96M
Diagnostics & Research
Services-medical Laboratories
Link
United States
MADISON